Biotech Leaders Reveal 2025's Most Promising Clinical Trials

What's heating up in pharma? Drug Discovery News asked industry experts which emerging therapies have them most excited this year. Here's what they said:

🩸 Blood Cancer Breakthrough

Tim Campbell, VP at Bristol Myers Squibb
"As a hematologist, I'm watching menin inhibitors for acute myeloid leukemia (AML). After decades of limited options, these novel therapies show stunning early promise—especially in combination treatments."

🧬 Gene Therapy Revolution

Sandi See Tai, Lexeo Therapeutics
"2025 could be gene therapy's breakout year. With FDA fast-tracking treatments for Huntington's and Fabry diseases, we're entering an era where rare diseases may finally meet their match."

🧠 Neuro & Psychedelic Frontiers

Johan Luthman, Lundbeck
"Beyond next-gen MS immunotherapies, the real wildcard is psychedelic-assisted therapy. J&J's esketamine paved the way—now we'll see if others can deliver on this controversial approach."

🧪 Fighting Protein Misfolding

Claudio Soto, UT Health Houston
"For neurodegenerative diseases, antisense oligonucleotides could be game-changers. Instead of cleaning up protein aggregates, we're cutting off their supply—like stopping a flood at the source."

🎯 Multi-Target Mastery

Robert Lisicki, Zura Bio
"Bispecific antibodies represent the next evolution—one drug hitting multiple disease pathways simultaneously. For rare conditions, this precision could be transformative."

🦠 Hepatitis B Hope

Lawrence Blatt, Aligos Therapeutics
"New CHB therapies are shattering old treatment ceilings. We're closer than ever to functional cures for this global health burden."

Why This Matters
From cancer to neurodegeneration, 2025's pipeline blends cutting-edge science with urgent patient needs. One theme unites all these experts: the future of medicine is targeted, combinatory, and patient-centric.